`
`
`
`
`
`
`
`
`June 15, 2021
`
`Certification
`
`Welocalize Translations
`
`
`
`This is to certify that the attached translation is, to the best of my knowledge and
`belief, a true and accurate translation from Norwegian into English of the file
`“Ref Møte U H 050506_726_Word”.
`
`
`
`
`
`
`_________________________________
`
`Keimi Kanno
`
`Project Manager
`
`Project Number: CAJO_2106_P0014
`
`
`
`
`AKER EXHIBIT 2006 PAGE 0001
`
`

`

`Meeting with Ulf Håkansson, Plant Leader Brunna, Fresenius Kabi (FK) 05.05.06.
`
`Present: Nils Are Lysø, Finn-Arne Lorentsen, Einar Lied and Snorre Tilseth.
`
`NAL og FAL presented Aker's business.
`
`UH : The factory in Brunna is specifically built for production of PL from egg yolk
`powder (EPL). The Pl content is 20% and is paid with SKK 45/kg to the producer. The
`product is approved for use in medication. The factory has 50% of the world's production
`of 200 tons/year. Brunna supplies EPL concentrates to 30 FK factories in various
`countries, which produce parenteral fluids (parenteral = intravenous nutrition versus
`enteral = drink) for medical clinical nutrition. He also has a few different external
`customers without these being specified. Closest competitor has 25% of the market.
`There is a total of only 4 players in the market.
`
`Of the EPL emulsions 90% go to clinical nutrition and only 10% to pharma emulsions,
`e.g. Diprivan (anesthesia) AstraZenica.
`
`Today only EPL is approved for medical use. The pharmaceutical industry in the
`industrialized part of the world is saturated with this product, and the market has a
`weak annual growth. The increase will first and foremost come in South East Asia.
`
`The by-product after the extraction is denaturalized egg yolk protein. This is sold to the
`food industry, and is used as a supplement in baked goods with a growing market,
`especially in Eastern Europe.
`
`The last years, FK has tested different raw materials for extraction of marine - PL (MPL)
`such as cod roe, milt, fishmeal and other by-products from fish without this giving results
`that can be used industrially. FK has been looking for an industrial supplier of raw
`materials for extraction of MPL.
`
` A
`
` test extraction of our krill flour gave good results, both mhp yield of PL (fat classes not
`analyzed) and technically in the process. Want to run pilot scale trial with 300 – 400 kg
`krill flour. (Calls ST when the material is to be sent.)
`
`Ulf Håkansson has during the last four-year period worked on ideas to develop new
`products geared towards the nutrition market based on the surplus capacity in the factory
`in Brunna (first section extraction, the bottle neck sites in the last step for up-
`concentration). He has a clear opinion that marine PL with its specific characteristics
`quickly could take over the market from existing products within nutraseuticals,
`functional foods. (The factory in Brunna can also separate the lipid classes, also the
`different pl-components; this is something we can develop further within health food or
`further within pharma.)
`
`
`
`
`AKER EXHIBIT 2006 PAGE 0002
`
`

`

`
`Ulf exemplified this with:
`
`Breast milk substitute, which in today's product, among others, contains 50% EPL mixed
`with 50% rapeseed oil (SKR 5/kg) paid with SKR 300/kg (i.e. SKR 600/kg EPL). The
`market in Europe is 20 – 30 tons.
`He also thinks that we may be able to get in with a series of other products as alternative
`to the food industry, then imagined as nurtaceuticals/ functional foods, (health food are
`tablets and capsules) both for emulsions and/or by-products like the protein part (if
`nothing else, we ourselves will have customers within the specialty feed market).
`
` 1
`
` 1/2 years ago, Ulf was contacted by Cargill, (family-owned, not listed on the Stock
`Exchange, world-wide supplier to the food industry) with a request for co-operation
`within extraction of PL. Cargill is positive to co-opetration with FK Brunna.
`
`Ulf's proposal for a co-operation model is based on “open books, shared cost and profit”
`built on mutual trust. He has envisioned Aker (krill flour producer, world leading) - FK
`Brunna (extraction, world leading) – Cargill (world leading) with over 150 market
`enterprises (largest supplier to McDonald) as a strong and leading alliance within
`production of nutraceuticals. The entity will be leading and dominating the market,
`defining the price level, and we think, quickly be able to get to market volumes of 1000
`tons and more. There are no problems with the logistics in Brunna to be able to handle
`this. (Question if it would not be a good idea in the future to set up a factory in South
`America to cut cost).
`
`As factory leader, Ulf has had the opportunity for entrepreneurship, leadership and
`decision lines within FK are short. The idea to co-operate with Aker is already discussed
`with FK's factory leader at the headquarter in Frankfurt, and positive signals for further
`negotiations have been given.
`
`We outlined 3 different models;
`
`one where Aker and FK start a run towards pharma for testing (all phases) for approval as
`a pharmaceutical product,
`
`one solution in alliance with Cargill, and
`
` a
`
` third solution where we rent produce at FK and distribute ourselves.
`
`
` Ulf is initially open to all suggestions. Agreement that if we enter into an alliance with
`Cargill, we do so together.
`
`Agreement that we at this stage discuss different forms of co-operation orally; we must
`return with a proposal on what form we would like.
`
`
`AKER EXHIBIT 2006 PAGE 0003
`
`

`

`The next meeting is in Brunna on the morning of May 19th – draft for co-operation
`model must be ready by May 29, 2006.
`
`During the meeting it was said that Cargill has purchased parts of Degussa – Degussa has
`made an agreement with Neptune to develop the market for phospholipids from krill oil.
`It must be determined if this may create problems with co-operation with Cargill. We are
`checking this via our contact in Canada.
`
`ST 05.07.06.
`
`AKER EXHIBIT 2006 PAGE 0004
`
`